{
    "clinical_study": {
        "@rank": "48805", 
        "brief_summary": {
            "textblock": "To examine the safety and tolerance of three doses of oral vesnarinone in HIV-infected\n      patients with CD4 count > 300 cells/mm3."
        }, 
        "brief_title": "A Phase I Study of Three Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons With CD4+ Cell Number > 300 Cells/mm3", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Twelve patients per dose level receive vesnarinone at 1 of 3 doses for 12 weeks. At least\n      six patients at a given dose level must have completed 2 weeks of treatment before dose is\n      escalated in subsequent patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Chemoprophylaxis for Pneumocystis carinii, candida, mycobacteria, and herpes simplex.\n\n        Patients must have:\n\n          -  Asymptomatic HIV infection.\n\n          -  CD4 count > 300 cells/mm3.\n\n          -  No prior AIDS-defining illness or current constitutional symptoms of HIV disease.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Current history of cardiac disease, including patients who exhibit long QT syndrome\n             on EKG screening.\n\n          -  Active malignancy other than cutaneous basal cell carcinoma or in situ carcinoma of\n             the cervix.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Antiretroviral agents, including ddI, ddC, and AZT.\n\n          -  Immunosuppressive agents.\n\n          -  Investigational HIV drugs/therapies including vaccines.\n\n          -  Interferon.\n\n          -  Steroids (other than topical).\n\n          -  Hematopoietins.\n\n          -  Megestrol acetate.\n\n          -  Trimethoprim/sulfamethoxazole in excess of 160 mg trimethoprim and 800 mg\n             sulfamethoxazole thrice weekly.\n\n          -  Cytotoxic chemotherapy.\n\n        Concurrent Treatment:\n\n        Excluded:\n\n          -  Radiation therapy.\n\n        Patients with the following prior conditions are excluded:\n\n          -  Prior history of cardiac disease.\n\n          -  History of agranulocytosis or severe (grade 3) drug-induced neutropenia or documented\n             abnormalities in granulocyte number or function.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  AZT, ddI, and ddC within 14 days prior to study entry.\n\n          -  Prior cytotoxic chemotherapy.\n\n        Prior Treatment:\n\n        Excluded:\n\n          -  Radiation therapy (including electron beam irradiation) within 30 days prior to study\n             entry.\n\n        Active illicit drug abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "36", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002129", 
            "org_study_id": "234A", 
            "secondary_id": "22-93-251"
        }, 
        "intervention": {
            "intervention_name": "Vesnarinone", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Vesnarinone"
        }, 
        "keyword": "vesnarinone", 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "900121973"
                }, 
                "name": "UCLA School of Medicine"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I Study of Three Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons With CD4+ Cell Number > 300 Cells/mm3", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "reference": {
            "citation": "Mitsuyasu R, Bort L, Miles SA, Hardy WD, Petit RG. Preliminary results of a phase I study of vesnarinone (OPC-8212) in HIV-infected persons with CD4 > 300 cells/MM3. Int Conf AIDS. 1994 Aug 7-12;10(1):8 (abstract no 005B)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002129"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Otsuka America Pharmaceutical", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 1996"
    }, 
    "geocoordinates": {
        "UCLA School of Medicine": "34.052 -118.244"
    }
}